Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-remitting Multiple Sclerosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jan 12

PMID 23308186

Citations 17

Authors

Diego Cadavid

Stephanie Jurgensen

Sophia Lee

Affiliations

Soon will be listed here.

Abstract

Background: There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis.

Objectives: Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS).

Methods: We retrospectively reviewed ambulatory function as measured by timed 25-foot walk (T25FW) in clinical trial subjects with an Expanded Disability Status Scale score ≥3.5, including RRMS subjects from the phase 3 AFFIRM and SENTINEL trials, relapsing SPMS subjects from the phase 2 MS231 study, and nonrelapsing SPMS subjects from the phase 1b DELIVER study. For comparison, SPMS subjects from the intramuscular interferon beta-1a (IM IFNβ-1a) IMPACT study were also analyzed. Improvement in ambulation was measured using T25FW responder status; response was defined as faster walking times over shorter (6-9-month) or longer (24-30-month) treatment periods relative to subjects' best predose walking times.

Results: There were two to four times more T25FW responders among disabled MS subjects in the natalizumab arms than in the placebo or IM IFNβ-1a arms. Responders walked 25 feet an average of 24%-45% faster than nonresponders.

Conclusion: Natalizumab improves ambulatory function in disabled RRMS subjects and may have efficacy in disabled SPMS subjects. Confirmation of the latter finding in a prospective SPMS study is warranted.

Citing Articles

Drug Delivery to the Brain: Recent Advances and Unmet Challenges.

Bhunia S, Kolishetti N, Vashist A, Arias A, Brooks D, Nair M Pharmaceutics. 2023; 15(12).

PMID: 38139999 PMC: 10747851. DOI: 10.3390/pharmaceutics15122658.

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.

Pardridge W Front Drug Deliv. 2023; 3.

PMID: 37583474 PMC: 10426772. DOI: 10.3389/fddev.2023.1227816.

Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?.

Siafaka P, Okur M, Erim P, Caglar E, Ozgenc E, Gundogdu E Pharmaceutics. 2022; 14(11).

PMID: 36365243 PMC: 9698227. DOI: 10.3390/pharmaceutics14112425.

What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?.

Kramer J, Wiendl H Neurotherapeutics. 2022; 19(3):785-807.

PMID: 35794296 PMC: 9294122. DOI: 10.1007/s13311-022-01246-3.

Involvement of cytotoxic Eomes-expressing CD4 T cells in secondary progressive multiple sclerosis.

Raveney B, Sato W, Takewaki D, Zhang C, Kanazawa T, Lin Y Proc Natl Acad Sci U S A. 2021; 118(11).

PMID: 33836594 PMC: 7980371. DOI: 10.1073/pnas.2021818118.

References

Orbach R, Zhao Z, Wang Y, ONeill G, Cadavid D . Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One. 2012; 7(10):e45409. PMC: 3462180. DOI: 10.1371/journal.pone.0045409. View

Cutter G, Baier M, Rudick R, Cookfair D, Fischer J, Petkau J . Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999; 122 ( Pt 5):871-82. DOI: 10.1093/brain/122.5.871. View

Rudick R, Stuart W, Calabresi P, Confavreux C, Galetta S, Radue E . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):911-23. DOI: 10.1056/NEJMoa044396. View

Phillips J, Giovannoni G, Lublin F, OConnor P, Polman C, Willoughby E . Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011; 17(8):970-9. DOI: 10.1177/1352458511399611. View

Aloisi F, Columba-Cabezas S, Franciotta D, Rosicarelli B, Magliozzi R, Reynolds R . Lymphoid chemokines in chronic neuroinflammation. J Neuroimmunol. 2008; 198(1-2):106-12. PMC: 7125843. DOI: 10.1016/j.jneuroim.2008.04.025. View

Kragt J, van der Linden F, Nielsen J, Uitdehaag B, Polman C . Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler. 2006; 12(5):594-8. DOI: 10.1177/1352458506070768. View

Howell O, Reeves C, Nicholas R, Carassiti D, Radotra B, Gentleman S . Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011; 134(Pt 9):2755-71. DOI: 10.1093/brain/awr182. View

Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen J . Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009; 73(23):2003-10. DOI: 10.1212/WNL.0b013e3181c5b457. View

Goodman A, Brown T, Krupp L, Schapiro R, Schwid S, Cohen R . Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009; 373(9665):732-8. DOI: 10.1016/S0140-6736(09)60442-6. View

10.

Vermersch P, Kappos L, Gold R, Foley J, Olsson T, Cadavid D . Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011; 76(20):1697-704. DOI: 10.1212/WNL.0b013e31821a446b. View

11.

Goldman M, Motl R, Rudick R . Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 2010; 3(4):229-39. PMC: 3002657. DOI: 10.1177/1756285610374117. View

12.

Cadavid D, Tang Y, ONeill G . [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. Rev Neurol. 2010; 51(6):321-9. View

13.

Paltamaa J, Sarasoja T, Leskinen E, Wikstrom J, Malkia E . Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory. Phys Ther. 2007; 88(2):176-90. DOI: 10.2522/ptj.20070064. View

14.

Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A . Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler. 2004; 10(1):41-6. DOI: 10.1191/1352458504ms983oa. View

15.

Leung G, Sun W, Brookes S, Smith D, Shi R . Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis. Exp Neurol. 2010; 227(1):232-5. PMC: 3019253. DOI: 10.1016/j.expneurol.2010.11.004. View

16.

Hoogervorst E, Kalkers N, Cutter G, Uitdehaag B, Polman C . The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler. 2004; 10(1):55-60. DOI: 10.1191/1352458504ms972oa. View

17.

Magliozzi R, Howell O, Reeves C, Roncaroli F, Nicholas R, Serafini B . A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010; 68(4):477-93. DOI: 10.1002/ana.22230. View

18.

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130(Pt 4):1089-104. DOI: 10.1093/brain/awm038. View

19.

Goldman M, Marrie R, Cohen J . Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2007; 14(3):383-90. DOI: 10.1177/1352458507082607. View

20.

Panitch H, Miller A, Paty D, Weinshenker B . Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004; 63(10):1788-95. DOI: 10.1212/01.wnl.0000146958.77317.3e. View